Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Home
/
update
/
details

APIS Announces Partnership with Shiva Scientific to Distribute ESR1 Mutations Kit in India

NextEdge Admin

02 Aug 2024

2 min 7 sec

APIS announced a strategic partnership with Shiva Scientific, naming them the exclusive distributor of the APIS ESR1 Mutations Kit in India. This collaboration underscores APIS's commitment to enhancing disease prediction and prevention on a global scale.

The APIS ESR1 Mutations Kit is a state-of-the-art qPCR assay designed for the sensitive and accurate detection of mutations in the oestrogen receptor gene. This qualitative test identifies eleven ESR1 mutations across exons 5, 7, and 8, including E380Q, S463P, P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N, and D538G. Utilizing mutation-specific probes and PCR clamp and blocker technology, the kit ensures specific amplification of mutant sequences even in the presence of a high wild-type background.

Key benefits of the APIS ESR1 Mutations Kit include:

- Wide target coverage: Detects 11 different ESR1 mutations.
- High specificity: Clamp and blocking technology prevents wild-type detection.
- High sensitivity: Detects mutations at ≤ 1% MAF (Mutant Allele Frequency).
- User-friendly: Simple protocol with optimized reagents for precise detection in human DNA.

Suitable for both centralized and decentralized settings, the APIS ESR1 Mutations Kit offers a reliable testing solution without the need for additional specialized equipment such as NGS, making it accessible and practical for various facilities. This partnership marks a significant step in advancing molecular pathology workflows in India.